UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010353
Receipt number R000009797
Scientific Title An open label,randomized control study for the comparison of pliotropic effects between Glulisine and Glargine with type 2 diabetes
Date of disclosure of the study information 2014/03/28
Last modified on 2014/12/16 13:55:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

An open label,randomized control study for the comparison of pliotropic effects between Glulisine and Glargine with type 2 diabetes

Acronym

An open label,randomized control study for the comparison of pliotropic effects between Glulisine and Glargine with type 2 diabetes

Scientific Title

An open label,randomized control study for the comparison of pliotropic effects between Glulisine and Glargine with type 2 diabetes

Scientific Title:Acronym

An open label,randomized control study for the comparison of pliotropic effects between Glulisine and Glargine with type 2 diabetes

Region

Japan


Condition

Condition

type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To compare the pleiotropic effects including glucose metabolism on patients with type 2 Diabetes between Bolus First (insulin glulisine three times daily) and Basal First Insulin (insulin glargine at bedtime)

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

M values

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Insulin glulisine was Administered before every meals.
Insulin dose is adjusted every day based on the results of blood glucose self-measurement.

Interventions/Control_2

insulin glargine was Administered before every sleeps. Initial insulin dose is calculated from the following equation.
Insulin dose is adjusted every day based on the results of blood glucose self-measurement.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The subjects must satisfy the following conditions:
1) An age at the time of obtaining informed consentis more than 20 years old
2) Patients with type 2 diabetes, whose HbA1c is more than 7.4%.
3) Gender is unquestioned:
4) Patients who are admitted to the purpose of glycemic control more than two weeks

Key exclusion criteria

1.Hypersensitivity to components of the insulin glargine and insulin glulisine.
2.None Type 2 diabetes
3.Medical history and/or complication of diabetic ketoacidosis.
4.Medical history and/or complication of severe hypoglycemia.
5.severe infection, around surgery or severe trauma.
6.Patients who received the administration of insulin, DPP-4 inhibitors or GLP-1 analog formulation within 4 weeks.
7.Treatment with glucocorticoid.
8.Uncontrolled Hypertension(systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg)
9.Proliferative retinopathy or maculopathy.
10.History of malignancy.
11.Severe health problems not suitable for the study.
12.Patients participated in other clinical trials within one month before the study.
13.Cases that Physicians deem inappropriate as the target of the test.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name TAKAMURA Toshinari

Organization

kanazawa University Graduate School of Medical Science.

Division name

Department of Disease control and homeostasis

Zip code


Address

13-1 Takara-machi, kanazawa, Ishikawa, Japan

TEL

076-265-2234

Email

ttakamura@m-kanazawa.jp


Public contact

Name of contact person

1st name
Middle name
Last name TAKAMURA Toshinari

Organization

kanazawa University Graduate School of Medical Science.

Division name

kanazawa University Graduate School of Medical Science.

Zip code


Address

13-1 Takara-machi, kanazawa, Ishikawa

TEL

076-265-2234

Homepage URL


Email

ttakamura@m-kanazawa.jp


Sponsor or person

Institute

Department of Disease Control and Homeostasis,kanazawa University Graduate School of Medical Science.

Institute

Department

Personal name



Funding Source

Organization

Department of Disease Control and Homeostasis,kanazawa University Graduate School of Medical Science.

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 03 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 05 Month 17 Day

Date of IRB


Anticipated trial start date

2011 Year 06 Month 01 Day

Last follow-up date

2014 Year 06 Month 01 Day

Date of closure to data entry

2014 Year 12 Month 01 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 03 Month 29 Day

Last modified on

2014 Year 12 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009797


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name